ANNUAL REPORT - Pevion Biotech AG

HIGHLIGHTS IN 2005
2005 ANNUAL REPORT
� Important steps forward in clinical development
Pevion Biotech’s lead product, a multi-component malaria vaccine
candidate, entered clinical Phase II. Positive interim results concerning
immunogenicity and safety were announced in December 2005.
� Achievements in product development
In 2005 two projects reached preclinical status and are ready to enter a
clinical phase I trial. One project aims for the development of a breast
cancer vaccine, a collaboration with Bio Life Science, Vienna, and another
project involves the HCV therapeutic vaccine candidate, representing Pevion
Biotech’s approach for a multi-epitope and personalized therapeutic
regimen.
� New vaccine candidate in the pipeline
To strengthen Pevion Biotech’s pipeline, a diphtheria/tetanus vaccine was
integrated into Pevion Biotech’s development plan. The vaccine candidate
will be a premium booster vaccine for adults and have a considerably higher
safety profile than conventional applications currently available in the
market.
� Increased stability for virosome vaccines
In 2005 a new virosome-manufacturing process called lyophilization was
established. This process is a groundbreaking innovation for virosome
technology. It improves the stability and the formulation of pharmaceutically
active substances.
� GMP certificate for manufacturing
Pevion Biotech’s quality system was approved by the national registration
authority Swissmedic, and the certificate of GMP Compliance of a
manufacturer was issued. It certifies that Pevion Biotech is authorized to
manufacture up to Phase III clinical trial products in collaboration with Berna
Crucell.
� Newly established strategic collaborations
Pevion Biotech’s virosome carrier/adjuvant technology platform provided
the basis for a number of strategic alliances with international biotechnology
companies, including Innogenetics (INNX; Ghent Belgium) and Mymetics
(MYMX; NYC, NY).
Additionally, Pevion Biotech signed an option agreement for an exclusive
license with Vivalis SA. The license grants a more favorable production
process of Hemagglutinin, an important component of Pevion Biotech’s
virosome technology.
� Intellectual property
Pevion Biotech further extended its patent portfolio by filing two
applications covering specific aspects of its virosome carrier. The IP portfolio
grew in 2005 to eleven patent applications. Additionally, the company has
exclusive licenses for four patent families with more than 90 granted patents.
In 2005 the company became registered owner of the trademarks “Pevion”,
“Pevion Biotech”, “PeviPRO TM” , “PeviTER TM ” and “Pevi TM ” in Switzerland, the
United States and the European Union.
Pevion Biotech_Annual Report2005_01_01_04_004 4/13